Chemodynamic therapy (CDT) involves the catalytic generation of highly toxic hydroxyl radicals (.OH) from hydrogen peroxide (H2O2) through metal‐ion‐mediated Fenton or Fenton‐like reactions. Fe2+ is a classical catalyst ion, however, it suffers easy oxidation and systemic side‐effects. Therefore, the development of a controllable Fe2+ delivery system is a challenge to maintain its valence state, reduce toxicity, and improve therapeutic efficacy. Reported here is a near‐infrared (NIR) light‐triggered Fe2+ delivery agent (LET‐6) for fluorescence (FL) and photoacoustic (PA) dual‐modality imaging guided, photothermal primed CDT. Thermal expansion caused by 808 nm laser irradiation triggers the transformation of LET‐6 to expose Fe2+ from its hydrophobic layer, which primes the catalytic breakdown of endogenous H2O2 within the tumor microenvironment, thus generating .OH for enhanced CDT. LET‐6 shows remarkable therapeutic effects, both in vitro and in vivo, achieving 100 % tumor elimination after just one treatment. This high‐performance Fe2+ delivery system provides a sound basis for future synergistic metal‐ion‐mediated cancer therapy.

New three-coordinate organoboron compounds functionalized by a (1-naphthyl)phenylamino group, B(mes) 2 (dbp-NPB) (1), B(db-NPB) 3 (2), and B(dbp-NPB) 3 (3), have been synthesized. A variable temperature 1 H NMR study showed that the aryl groups around the boron center in these compounds have a rotation barrier y70 kJ mol 21 . The new boron compounds are amorphous solids with T g being 110 uC, 171 uC and 173 uC, respectively. The electronic properties of the new boron compounds were investigated by cyclic voltammetry and UV-visible spectroscopy. All three boron compounds are blue emitters in the solid state. In solution the emission spectra of the boron compounds shift toward a longer wavelength with increasing solvent polarity. In CH 2 Cl 2 , the emission quantum efficiency of the three compounds was determined to be 0.22, 0.27 and 0.23, respectively. Several series of electroluminescent (EL) devices where compounds 1-3 are used as either an emitter/electron transport material, a hole transport material, or a hole injection material have been fabricated and their performance has been compared to the corresponding devices of BNPB, a previously investigated molecule, NPB, a commonly used hole transport material, and CuPc, a commonly used hole injection material. The EL results indicate that the new boron compounds are not suitable as emitters/electron transport materials, but they are promising as hole transport and hole injection materials in EL devices. ExperimentalAll starting materials were purchased from Aldrich Chemical Company and used without further purification. Solvents were freshly distilled over appropriate drying reagents. All experiments were carried out under a dry nitrogen atmosphere using

Neuropathic pain (NP) is a sustained and nonreversible condition characterized by long-term devastating physical and psychological damage. Therefore, it is urgent to identify an effective treatment for NP. Unfortunately, the precise pathogenesis of NP has not been elucidated. Currently, the microbiota-gut-brain axis has drawn increasing attention, and the emerging role of gut microbiota is investigated in numerous diseases including NP. Gut microbiota is considered as a pivotal regulator in immune, neural, endocrine, and metabolic signaling pathways, which participates in forming a complex network to affect the development of NP directly or indirectly. In this review, we conclude the current understanding of preclinical and clinical findings regarding the role of gut microbiota in NP and provide a novel therapeutic method for pain relief by medication and dietary interventions.

Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electronic databases PubMed, Medline, EMBASE, Web of Science and Cochrane Library and the clinical trial registry were searched for published and unpublished randomized clinical trials on humans. Eligible studies were RCTs conducted in patients with type 2 diabetes mellitus, comparing DPP4i with a placebo or other active drugs. A total of 72 trials with 35,768 and 33,319 patients enrolled for DPP4i and the comparison drugs, respectively. Overall, no significant associations were detected between the use of DPP4i and cancer development, in comparison with the use of other active drugs or placebo. The results were consistent across pre-defined subgroups stratified by type of DPP4i, type of cancer, drug for comparison, trial duration, or baseline characteristics. The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs.